Assessment of Patients Treated with Albiglutide - Phase 1

Trial description: Albiglutide, a Glucagon-like peptide-1 (GLP-1) receptor agonist, is a once-weekly injection of albiglutide approved as an adjunct to diet and exercise in adults with type 2 diabetes mellitus (T2DM) to improve glycemic control. This study will be completed in two phases: Phase 1 of this study was exploratory and Phase 1B will be conducted to examine the reproducibility of Phase 1 objectives over a 6-month period. This study is a retrospective database study with a goal to characterize early users of albiglutide and to assess the efficacy of albiglutide as measured by change in Glycated Hemoglobin (HbA1c) in both phases, and to examine medication persistence in subjects who initiate treatment with albiglutide in Phase 1B only. All subjects will be required to be continuously enrolled in the health plan for a minimum of 12 months. The date of the first filled prescription for albiglutide during the period will be identified as the index date. The six months prior to the index date ("baseline period") will be used to assess baseline characteristics. The six months following and inclusive of the index date ("follow up period") will be used to assess Proportion of Days Covered (PDC), number of albiglutide fills, and the albiglutide persistence/discontinuation; the 30 days prior to and following the six-month follow-up period (index date +151 through index date+211 days) will be used to assess HbA1c outcomes.